Pacira BioSciences, Inc. reported a 29% increase in total revenues for the fourth quarter of 2019, reaching $122.4 million, driven by a 24% increase in EXPAREL net product sales and iovera° net product sales of $3.2 million. The company's GAAP net loss was $4.9 million, or $0.12 per share, while non-GAAP net income was $23.8 million, or $0.56 per share. Pacira also provided full-year 2020 revenue guidance of between $485 million and $500 million.
Total revenues increased by 29% to $122.4 million compared to Q4 2018.
EXPAREL net product sales increased by 24% to $116.9 million compared to Q4 2018.
iovera° net product sales were $3.2 million.
Non-GAAP net income was $23.8 million, or $0.56 per diluted share.
Pacira provided full-year 2020 financial guidance, expecting total revenues to be between $485 million and $500 million.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance